1
|
Mukunda DC, Rodrigues J, Joshi VK, Raghushaker CR, Mahato KK. A comprehensive review on LED-induced fluorescence in diagnostic pathology. Biosens Bioelectron 2022; 209:114230. [PMID: 35421670 DOI: 10.1016/j.bios.2022.114230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Revised: 03/19/2022] [Accepted: 03/25/2022] [Indexed: 11/02/2022]
Abstract
Sensitivity, specificity, mobility, and affordability are important criteria to consider for developing diagnostic instruments in common use. Fluorescence spectroscopy has been demonstrating substantial potential in the clinical diagnosis of diseases and evaluating the underlying causes of pathogenesis. A higher degree of device integration with appropriate sensitivity and reasonable cost would further boost the value of the fluorescence techniques in clinical diagnosis and aid in the reduction of healthcare expenses, which is a key economic concern in emerging markets. Light-emitting diodes (LEDs), which are inexpensive and smaller are attractive alternatives to conventional excitation sources in fluorescence spectroscopy, are gaining a lot of momentum in the development of affordable, compact analytical instruments of clinical relevance. The commercial availability of a broad range of LED wavelengths (255-4600 nm) has opened up new avenues for targeting a wide range of clinically significant molecules (both endogenous and exogenous), thereby diagnosing a range of clinical illnesses. As a result, we have specifically examined the uses of LED-induced fluorescence (LED-IF) in preclinical and clinical evaluations of pathological conditions, considering the present advancements in the field.
Collapse
Affiliation(s)
| | - Jackson Rodrigues
- Department of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka-576104, India
| | - Vijay Kumar Joshi
- Department of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka-576104, India
| | - Chandavalli Ramappa Raghushaker
- Department of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka-576104, India
| | - Krishna Kishore Mahato
- Department of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka-576104, India.
| |
Collapse
|
2
|
Corica D, Pepe G, Currò M, Aversa T, Tropeano A, Ientile R, Wasniewska M. Methods to investigate advanced glycation end-product and their application in clinical practice. Methods 2021; 203:90-102. [DOI: 10.1016/j.ymeth.2021.12.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2020] [Revised: 12/01/2021] [Accepted: 12/16/2021] [Indexed: 12/15/2022] Open
|
3
|
Safwat NA, ELkhamisy MM, Abdel-Wahab SEA, Hamza MT, Boshnak NH, Kenny MA. Polymorphisms of the receptor for advanced glycation end products as vasculopathy predictor in sickle cell disease. Pediatr Res 2021; 89:185-190. [PMID: 32544923 DOI: 10.1038/s41390-020-1014-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2020] [Revised: 06/03/2020] [Accepted: 06/04/2020] [Indexed: 11/09/2022]
Abstract
BACKGROUND The genetic variants of the receptor for advanced glycation end products (RAGE) gene have been associated with vascular disease risk. The objective of this work was to explore the association of three single-nucleotide polymorphisms (SNPs) of RAGE gene (374T/A, 429T/C, and G82S) with vascular complications in SCD. METHODS The study was conducted on 40 children with SCD and 40 healthy children served as controls. All participants were genotyped for the three studied RAGE polymorphisms by polymerase chain reaction (PCR). RESULTS Regarding 374T/A polymorphism, the frequency of TA, TT genotypes and T allele were higher in patients (p < 0.001). T allele was associated with higher incidence of sickling crisis and stroke (p < 0.05). In the subgroup analyses of 429T/C polymorphism, an association between C allele and SCD vascular complications was observed (p < 0.05). Concerning the frequency of G82S genotypes of RAGE, GG variant was detected in 39 (97.5%) of the patients, as compared with 40 (100%) of controls (p = 0.3). A regression analysis proved that HbS%, serum ferritin, and the -374T and 429C alleles were significant independent predictors of frequent sickling episodes (p < 0.05). CONCLUSIONS The C allele of -429T/C and T allele of 374T/A RAGE polymorphisms may be considered as predictors for vascular dysfunction in SCD. IMPACT The C allele of -429T/C and T allele of 374T/A RAGE polymorphisms may be considered as predictors for vascular dysfunction in SCD patients. To our knowledge, our study is the first exploring the association of three single-nucleotide polymorphisms of RAGE gene (374T/A, 429T/C, and G82S) with vascular complications in SCD. Early identification of patients carrying these genetic variants might be of great importance not only to identify subjects at risk of vasculopathy but also to direct them to RAGE-targeted treatments.
Collapse
Affiliation(s)
- Nesma Ahmed Safwat
- Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
| | - Mai Mohamed ELkhamisy
- Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | | | - Mohamed Tarif Hamza
- Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Noha Hussein Boshnak
- Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Mahmoud Adel Kenny
- Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| |
Collapse
|
4
|
Li J, Jeong SY, Xiong B, Tseng A, Mahon AB, Isaacman S, Gordeuk VR, Cho J. Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease. Haematologica 2020; 105:2407-2419. [PMID: 33054081 PMCID: PMC7556679 DOI: 10.3324/haematol.2019.226720] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 10/29/2019] [Indexed: 12/25/2022] Open
Abstract
Adherent neutrophils on vascular endothelium positively contribute to cell-cell aggregation and vaso-occlusion in sickle cell disease. In the present study, we demonstrated that pyridoxamine, a derivative of vitamin B6, might be a therapeutic agent to alleviate intravascular cell-cell aggregation in sickle cell disease. Using real-time intravital microscopy, we found that one oral administration of pyridoxamine dose-dependently increased the rolling influx of neutrophils and reduced neutrophil adhesion to endothelial cells in cremaster microvessels of sickle cell disease mice challenged with hypoxia-reoxygenation. Short-term treatment also mitigated neutrophil-endothelial cell and neutrophil-platelet interactions in the microvessels and improved the survival of sickle cell disease mice challenged with tumor necrosis factor-α. The inhibitory effects of pyridoxamine on intravascular cell-cell interactions were potentiated by co-treatment with hydroxyurea. We observed that long-term (5.5 months) oral treatment with pyridoxamine significantly diminished the adhesive function of neutrophils and platelets and down-regulated the expression of E-selectin and intercellular adhesion molecule-1 on the vascular endothelium in tumor necrosis factor-α-challenged sickle cell disease mice. Ex vivo studies revealed that the surface amount of αMβ2 integrin was significantly decreased in stimulated neutrophils isolated from sickle cell disease mice treated with pyridoxamine-containing water. Studies using platelets and neutrophils from sickle cell disease mice and patients suggested that treatment with pyridoxamine reduced the activation state of platelets and neutrophils. These results suggest that pyridoxamine may be a novel therapeutic and a supplement to hydroxyurea to prevent and treat vaco-occlusion events in sickle cell disease.
Collapse
Affiliation(s)
- Jing Li
- Department of Pharmacology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Si-Yeon Jeong
- Department of Pharmacology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Bei Xiong
- Department of Pharmacology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
- Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P.R. China
| | - Alan Tseng
- Department of Pharmacology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | | | | | - Victor R. Gordeuk
- Section of Hematology/Oncology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
- Comprehensive Sickle Cell Center, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Jaehyung Cho
- Department of Pharmacology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| |
Collapse
|
5
|
Charrin E, Faes C, Sotiaux A, Skinner S, Pialoux V, Joly P, Connes P, Martin C. Receptor for Advanced Glycation End Products Antagonism Blunts Kidney Damage in Transgenic Townes Sickle Mice. Front Physiol 2019; 10:880. [PMID: 31396093 PMCID: PMC6663971 DOI: 10.3389/fphys.2019.00880] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Accepted: 06/24/2019] [Indexed: 01/04/2023] Open
Abstract
A large proportion of adult patients with sickle cell disease (SCD) develops kidney disease and is at a high risk of mortality. The contribution of advanced glycation end products and their receptor (AGE/RAGE) axis has been established in the pathogenesis of multiple kidney diseases. The aim of the present study was to determine the implication of RAGE in the development of SCD-related kidney complications in a mouse model of SCD, as this has never been investigated. 8-week-old AA (normal) and SS (homozygous SCD) Townes mice were treated with a specific RAGE antagonist (RAP) or vehicle (NaCl). After 3 weeks of treatment, red blood cell count, hematocrit, and hemoglobin levels were significantly higher in RAP-treated SS mice. Reticulocyte count and sickle cell count were reduced in RAP-SS compared to their NaCl-treated littermates. The lower NADPH oxidase activity in the kidney of RAP-treated mice compared to NaCl-treated mice suggests limited ROS production. RAP-treated SS mice had decreased NF-κB protein expression and activation as well as reduced TNF-α mRNA expression in the kidney. Glomerular area, interstitial fibrosis, tubular iron deposits, and KIM-1 protein expression were significantly reduced after RAP treatment. In conclusion, this study provides evidence supporting the pathogenic role of RAGE in kidney injuries in sickle cell mice.
Collapse
Affiliation(s)
- Emmanuelle Charrin
- Interuniversity Laboratory of Human Movement Biology, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.,Laboratory of Excellence "GR-Ex", Paris, France
| | - Camille Faes
- Interuniversity Laboratory of Human Movement Biology, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.,Laboratory of Excellence "GR-Ex", Paris, France
| | - Amandine Sotiaux
- Interuniversity Laboratory of Human Movement Biology, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.,Laboratory of Excellence "GR-Ex", Paris, France
| | - Sarah Skinner
- Interuniversity Laboratory of Human Movement Biology, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.,Laboratory of Excellence "GR-Ex", Paris, France
| | - Vincent Pialoux
- Interuniversity Laboratory of Human Movement Biology, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.,Laboratory of Excellence "GR-Ex", Paris, France.,Institut Universitaire de France, Paris, France
| | - Philippe Joly
- Interuniversity Laboratory of Human Movement Biology, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.,Laboratory of Excellence "GR-Ex", Paris, France.,Groupement Hospitalier Est, UF "Biochimie des Pathologies érythrocytaires" Centre de Biologie Est, CHU de Lyon, Lyon, France
| | - Philippe Connes
- Interuniversity Laboratory of Human Movement Biology, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.,Laboratory of Excellence "GR-Ex", Paris, France.,Institut Universitaire de France, Paris, France
| | - Cyril Martin
- Interuniversity Laboratory of Human Movement Biology, University Claude Bernard Lyon 1, University of Lyon, Lyon, France.,Laboratory of Excellence "GR-Ex", Paris, France
| |
Collapse
|
6
|
Vongsanim S, Fan S, Davenport A. Comparison of skin autofluorescence, a marker of tissue advanced glycation end-products in peritoneal dialysis patients using standard and biocompatible glucose containing peritoneal dialysates. Nephrology (Carlton) 2019; 24:835-840. [PMID: 30298704 DOI: 10.1111/nep.13510] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/02/2018] [Indexed: 11/30/2022]
Abstract
BACKGROUND Heat sterilization of peritoneal dialysis (PD) dialysates leads to the generation of advanced glycation products (AGE), which can then deposit in the skin and be measured by skin autofluorescence (SAF). Newer biocompatible dual chamber dialysates contain less AGE. We wished to determine whether the use of these newer dialysates resulted in lower SAF. METHODS Skin autofluorescence was measured using the AGE reader, which directs ultraviolet light, intensity range 300-420 nm (peak 370 nm) in patients established on PD for >3 months using glucose containing dialysates. RESULTS We screened 196 consecutive patients, and measured SAF in 150; 86 (57.3%) male, median age 62 (53-71) years, median duration of PD treatment 17 (8.6-34.3) months. The median SAF was 3.48 (2.92-4.26) AU. The median SAF in the 57 (38%) patients prescribed biocompatible dual chamber bag dialysates was 3.39 (2.69-3.98) versus 3.5 (3.05-4.54) for those using standard dialysates (P = 0.044). Although prescription of biocompatible fluids was associated with SAF on univariate analysis, but not on multivariable testing, SAF was independently associated with Stoke-Davies co-morbidity grade (β 0.045, 95% confidence limits (CL) 0.015-0.075, P = 0.002), log duration of PD therapy (β 0.051, CL 0.001-0.101, P = 0.045), white ethnicity (β 0.066, CL 0.028-0.104, P = 0.001), and negatively with serum albumin (β -0.006, CL -0.008 to -0.004, P = 0.014). CONCLUSION Although SAF was lower in PD patients prescribed biocompatible dual chamber dialysates, on multivariable testing these dialysates were not independently associated with SAF. Other factors than PD fluid AGE content appear more important in determining SAF.
Collapse
Affiliation(s)
- Surachet Vongsanim
- Renal Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Stanley Fan
- Department of Renal Medicine, Royal London Hospital, Barts Health NHS Trust, London, UK
| | - Andrew Davenport
- UCL Department of Nephrology, Royal Free Hospital, University College London, London, UK
| |
Collapse
|